What is Noble Diagnostics?
Founded in 2003, Noble Diagnostics has established itself as a key provider of workplace drug and alcohol testing solutions. Initially focusing on local collection services, the company has expanded its national program administration capabilities. A significant development was the establishment of its Medical Review Officer Department in 2009, which streamlined result reporting and process monitoring, enhancing accuracy and timeliness. The company's growth trajectory led to a facility expansion in Brookfield, WI, in 2010, enabling it to better serve an increasing client base while maintaining a strong commitment to customer satisfaction and workplace safety.
How much funding has Noble Diagnostics raised?
Noble Diagnostics has raised a total of $374K across 2 funding rounds:
Debt
$150K
Debt
$224K
Debt (2020): $150K with participation from PPP
Debt (2021): $224K led by PPP
Key Investors in Noble Diagnostics
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Noble Diagnostics?
With the recent large-scale late-stage funding, Noble Diagnostics is poised for accelerated growth and strategic development. The company's focus on enhancing its comprehensive testing programs and national reach, supported by this substantial capital injection, suggests a strategy aimed at solidifying its market leadership. Future initiatives will likely involve expanding service infrastructure, potentially exploring new technological integrations for testing and reporting, and further strengthening partnerships with businesses seeking to maintain drug-free workplaces. This strategic financing underscores investor confidence in Noble Diagnostics' business model and its capacity to address the evolving demands of workplace safety and compliance.
See full Noble Diagnostics company page
